Recent Updates
Recently added Catalysts
NAGE Positive Sentiment

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

Monday, September 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Niagen Bioscience, Inc. has announced a new preclinical study published in Nature Communications. The research identifies the CD38 enzyme as a significant contributor to the decline of NAD+ levels in aging tissues. Furthermore, it highlights that nicotinamide riboside (NR) can restore NAD+ levels, leading to improved outcomes in placental, fetal, and offspring health.

Market Sentiment Analysis

POSITIVE FACTORS

  • New research identifies CD38 as a key factor in NAD+ decline.
  • Nicotinamide riboside (NR) shows promise in restoring NAD+ levels.
  • Improved pregnancy outcomes linked to NAD+ restoration.
  • Study published in a reputable journal enhances credibility.

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary driver of NAD+ decline in aging tissue, and that nicotinamide riboside (NR) restored NAD+ and improved placental, fetal, and offspring

Frequently Asked Questions

What is the role of CD38 in NAD+ decline?

CD38 is identified as a primary driver of NAD+ decline in aging tissue.

How does nicotinamide riboside (NR) affect NAD+ levels?

Nicotinamide riboside (NR) restores NAD+ levels, improving health outcomes.

What were the findings related to pregnancy outcomes?

The study found that NAD+ restoration with NR improves placental and fetal health.

Where was the study published?

The research was published in the journal Nature Communications.

ShareAdd on Google
Tags: NAGE Viatris Investor Conferences Healthcare NAD+ nicotinamide riboside pregnancy outcomes aging CD38
Last updated: Sep 21, 2026

Biotech snapshot

Cash runway
$67M liquidity · $0M/mo burn
Low dilution risk
Lead asset
NiagenPlusPhase 1
Healthy Volunteer →